Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole in hormone receptor-positive recurrent or metastatic gynecological cancers
ISRCTN43261139Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in gynecological cancer, ovarian cancer, primary peritoneal cancer (PPC) and 9 more, sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Clinical benefit rate. Started Jan 2011; status: completed.
02
Drugs
anastrozole
03
Conditions
gynecological cancerovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)
Beyond the preview
Go deeper on ISRCTN43261139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43261139.